Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

Norihiro Nishimoto,Koichi Amano,Yasuhiko Hirabayashi,Takahiko Horiuchi,Tomonori Ishii,Mitsuhiro Iwahashi,Masahiro Iwamoto,Hitoshi Kohsaka,Masakazu Kondo,Tsukasa Matsubara,Toshihide Mimura,Hisaaki Miyahara,Shuji Ohta,Yukihiko Saeki,Kazuyoshi Saito,Hajime Sano,Kiyoshi Takasugi,Tsutomu Takeuchi,Shigeto Tohma,Tomomi Tsuru,Yukitaka Ueki,Jiro Yamana,Jun Hashimoto,Takaji Matsutani,M. Murakami,Nobuhiro Takagi

Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study

2013

Objectives To investigate the duration of remission and low disease activity (LDA) after cessation of tocilizumab (TCZ) treatment in rheumatoid arthritis patients who showed remission or LDA as assessed by DAS28 in response to preceding TCZ monotherapy, and to explore the factors contributing to prolonged efficacy duration.

Keywords:

Drug
Tocilizumab
Physical therapy
Rheumatoid arthritis
Disease
Diabetes mellitus
Interleukin 6
Medicine
Rheumatology
Antirheumatic Agents
Internal medicine
Severity of illness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations